Heparanase: A rainbow pharmacological target associated to multiple pathologies including rare diseases

Future Medicinal Chemistry

Volumn 8, Issue 6, 2016, Pages 647-680

  Rivara, Silvia ^a   Milazzo, Ferdinando M ^b   Giannini, Giuseppe ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

angiogenesis; cancer and metastasis; endo D glucuronidase; heparanase; heparanase in vitro assays; heparanase inhibitors; heparanase structure; inflammation; modified heparins; rare diseases

Indexed keywords

HEPARANASE; HEPARANASE INHIBITOR; INTEGRIN; NUCLEIC ACID; OLIGOSACCHARIDE; PG 545; POLYSACCHARIDE; RONEPARSTAT; UNCLASSIFIED DRUG; VACCINE; BETA GLUCURONIDASE;

AMYLOIDOSIS; ANGIOGENESIS; AVASCULAR NECROSIS; CANCER GROWTH; CLINICAL TRIAL (TOPIC); ENZYME ACTIVATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HEREDITARY MULTIPLE EXOSTOSIS; HUMAN; INFLAMMATION; OSSIFYING MYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RARE DISEASE; REVIEW; VULVODYNIA; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; CHEMISTRY; DIABETIC NEPHROPATHIES; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; OSTEOLYSIS; RARE DISEASES; THROMBOSIS; VASCULARIZATION;

ATHEROSCLEROSIS; BONE RESORPTION; DIABETIC NEPHROPATHIES; GLUCURONIDASE; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; RARE DISEASES; SUBSTRATE SPECIFICITY; THROMBOSIS;

EID: 84966473862     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2016-0012     Document Type: Review

References (224)

1. Nasser NJ, Nevo E. Heparanase patents: dim past and bright future. Recent Pat. Inflamm. Allergy Drug Discov. 7(2), 162-167 (2013).
2. Parish CR, Freeman C, Hulett MD. Heparanase: A key enzyme involved in cell invasion. Biochem. Biophys. Acta 1471(3), M99-M108 (2001).
3. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108(3), 341-347 (2001).
4. Vlodavsky I, Eldor A, Haimovitz-Friedman A et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metast. 12(2), 112-127 (1992).
5. Chen LG, Sanderson RD. Heparanase regulates levels of syndecan-1in the nucleus. PLoS ONE 4(3), e4947 (2009).
6. Richardson TP, Trinkaus-Randall V, Nugent MA. Regulation of heparin sulfate proteoglycan nuclear localization by fibronectin. J. Cell Sci. 114(Pt 9), 1613-1623 (2001).
7. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem. Sci. 34(10), 511-519 (2009).
8. Ilan N, Elkin M, Vlodavsky I. Regulation, function, and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 38(12), 2018-2039 (2006).
9. Reiland J, Kempf D, Roy M, Denkins Y, Marchetti D. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 8(7), 596-560 (2006).
10. Reiland J, Sanderson RD, Waguespack M et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J. Biol. Chem. 279(9), 8047-8055 (2004).
11. Mackenzie E, Tyson K, Stamps A et al. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem. Biophys. Res. Commun. 276(3), 1170-1177 (2000).
12. Mahmood S, Beetz C, Tahir MM et al. First Hpse2 missense mutation in urofacial syndrome. Clin. Genet. 81(1), 88-92 (2012).
13. Levy-Adam F, Feld S, Cohen-Kaplan V et al. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J. Biol. Chem. 285(36), 28010-28019 (2010).
14. Roberts NA, Woolf AS, Stuart HM et al. Heparanase 2, mutated in urofacial syndrome, mediates peripheral neural development in Xenopus. Hum. Mol. Genet. 23(16), 4302-4314 (2014).
15. Merchant ZM, Kim YS, Rice KG, Linhardt R. Structure of heparin-derived tetrasaccharides. Biochem. J. 229(2), 369-377 (1985).
16. Kim BT, Kim WS, Kim YS, Linhardt RJ, Kim DH. Purification and characterization of a novel heparinase from Bacteroides stercoris HJ-15. J. Biochem. 128(2), 323-328 (2000).
17. Davies GJ, Wilson KS, Henrissat B. Nomenclature for sugar-binding subsites in glycosyl hydrolases. Biochem. J. 321(Pt 2), 557-559 (1997).
18. Dong J, Kukula AK, Toyoshima M, Nakajima M. Genomic organization and chromosome localization of the newly identified human heparanase gene. Gene 253(2), 171-178, 2000.
19. Vlodavsky I, Friedmann Y, Elkin M et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5(7), 793-802 (1999).
20. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5(7), 803-809 (1999).
21. Kussie PH, Hulmes JD, Ludwig DL et al. Cloning and functional expression of a human heparanase gene. Biochem. Biophys. Res. Commun. 261(1), 183-187 (1999).
22. Fairbanks MB, Mildner AM, Leone JW et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J. Biol. Chem. 274(42), 29587-29590 (1999).
23. Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J. Biol. Chem. 274(34), 24153-24160 (1999).
24. Shteingauz A, Ilan N, Vlodavsky I. Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and {Alpha}-actinin. Cell Mol. Life Sci. 71(22), 4457-4470 (2014).
25. Fairbanks MB, Mildner AM, Leone JW et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J. Biol. Chem. 274(42), 29587-29590 (1999).
26. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J. Biol. Chem. 280(14), 13568-13575 (2005).
27. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparinderived mimetics of heparan sulfate. Curr. Pharm. Des. 13(20), 2057-2073 (2007).
28. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N. Heterodimer formation is essential for heparanase enzymatic activity. Biochem. Biophys. Res. Commun. 308(4), 885-891 (2003).
29. Shafat I, Vlodavsky I, Ilan N. Characterization of mechanisms involved in secretion of active heparanase. J. Biol. Chem. 281(33), 23804-23811 (2006).
30. Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I, Ilan N. Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS ONE 3(6), e2319 (2008).
31. Wu L, Viola CM, Brzozowski AM, Davies GJ. Structural characterization of human heparanase reveals insights into substrate recognition. Nat. Struct. Mol. Biol. 22(12), 1016-1022 (2015).
32. Barash U, Cohen-Kaplan V, Arvatz G et al. A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J. 24(4), 1239-1248 (2010).
33. Nasser NJ, Avivi A, Shushy M, Vlodavsky I, Nevo E. Cloning, expression, and characterization of an alternatively spliced variant of human heparanase. Biochem. Biophys. Res. Commun. 354(1), 33-38 (2007).
34. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, Steinkühler C. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43(7), 1862-1873 (2004).
35. Fux L, Feibish N, Cohen-Kaplan V et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 69(5), 1758-1767 (2009).
36. Wilson JC, Laloo AE, Singh S, Ferro V. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase. Biochem. Biophys. Res. Commun. 443(1), 185-188 (2014).
37. Hulett MD, Hornby JR, Ohms SJ et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39(51), 15659-15667 (2000).
38. Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I, Ilan N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J. Biol. Chem. 280(21), 20457-20466 (2005).
39. Peterson SB, Liu J. Multi-faceted substrate specificity of heparanase. Matrix Biol. 32(5), 223-227 (2013).
40. Mao Y, Huang Y, Buczek-Thomas JA et al. A liquid chromatography-mass spectrometry-based approach to characterize the substrate specificity of mammalian heparanase. J. Biol. Chem. 289(49), 34141-34151 (2014).
41. Bohlmann L, Tredwell GD, Yu X et al. Functional and structural characterization of a heparanase. Nat. Chem. Biol. 11(12), 955-957 (2015).
42. Zhou Z, Bates M, Madura JD. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design. Proteins 65(3), 580-592 (2006).
43. Gandhi NS, Freeman C, Parish CR, Mancera RL. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-d-glucuronidase (heparanase). Glycobiology 22(1), 35-55 (2012).
44. Fux L, Feibish N, Cohen-Kaplan V et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 69(5), 1758-1767 (2009).
45. Sapay N, Cabannes E, Petitou M, Imberty A. Molecular model of human heparanase with proposed binding mode of a heparan sulfate oligosaccharide and catalytic amino acids. Biopolymers 97(1), 21-34 (2012).
46. Vinader V, Haji-Abdullahi MH, Patterson LH, Afarinkia K. Synthesis of a pseudo-disaccharide library and its application to the characterisation of the heparanase catalytic site. PLoS ONE 8(11), e82111 (2013).
47. Pala D, Rivara S, Mor M et al. Kinetic analysis and molecular modelling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology (2016) (Epub ahead of print). http://glycob.oxfordjournals.org/content/early/
48. Nasser NJ. Heparanase involvement in physiology and disease. Cell Mol. Life Sci. 65(11), 1706-1715 (2008).
49. Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L, Kovalszky I. Proteoglycans and tumor progression: janusfaced molecules with contradictory functions in cancer. Semin. Cancer Biol. 12(3), 173-186 (2002).
50. Lindahl U, Kjellen L. Pathophysiokogy of heparin sulphate: many diseases, few drugs. J. Intern. Med. 273(6), 555-571 (2013).
51. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 15(5), 1013-1031 (2011).
52. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446(7139), 1030-1037 (2007).
53. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu. Rev. Biochem. 67, 609-652 (1998).
54. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28(3), 145-151 (2003).
55. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108(3), 341-347 (2001).
56. Gotte M. Syndecans in inflammation. FASEB J. 17(6), 575-591 (2003).
57. Vreys V, David G. Mammalian heparanase: what is the message? J. Cell. Mol. Med. 11(3), 427-452 (2007).
58. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb. Haemost. 102(5), 823-828 (2009).
59. Pisano C, Vlodavsky I, Ilan N, Zunino F. The potential of heparanase as a therapeutic target in cancer. Biochem. Pharmacol. 89(1), 12-19 (2014).
60. McKenzie EA. Heparanase: A target for drug discovery in cancer and inflammation. Br. J. Pharmacol. 151(1), 1-14 (2007).
61. Nadir Y, Brenner B. Heparanase multiple effects in cancer. Thromb. Res. 133(S2), S90-S94 (2014).
62. Hammond E, Khurana A, Shridhar V, Dredge K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front. Oncol. 4, 195 (2014).
63. Masola V, Secchi MF, Gambaro G, Onisto M. Heparanase as a target in cancer therapy. Curr. Cancer Drug Targets 14(3), 286-293 (2014).
64. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2(7), 521-528 (2002).
65. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24(25), 4037-4051 (2005).
66. Elkin M, Ilan N, Ishai-Michaeli R et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 15(9), 1661-1663 (2001).
67. Nakajima M, Irimura T, Nicolson GL. Heparanase and tumor metastasis. J. Cell. Biochem. 36(2), 157-167 (1988).
68. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenic arena. J. Clin. Invest. 108(3), 349-355 (2001).
69. Vlodavsky I, Miao H-Q, Medalion B, Danagher P, Ron D. Involvement of heparin sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev. 15(2), 177-186 (1996).
70. Purushothaman A, Uyama T, Kobayashi F et al. Heparanaseenhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115(12), 2449-2457 (2010).
71. Goldshmidt O, Zcharia E, Cohen M et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J. 17(9), 1015-1025 (2003).
72. He YQ, Sutcliffe EL, Bunting KL et al. The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription 3(3), 130-145 (2012).
73. Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J. Biol. Chem. 288(14), 10093-10099 (2013).
74. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res. 68(24), 10077-10085 (2008).
75. Ramani VC, Yang Y, Ren Y, Nan L, Sanderson RD. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J. Biol. Chem. 286(8), 6490-6499 (2011).
76. Purushothaman A, Babitz SK, Sanderson RD. Heparanase enhances the insulin receptor signaling pathway to activate ERK in multiple myeloma. J. Biol. Chem. 287(49), 41288-41296 (2012).
77. Cohen I, Pappo O, Elkin M et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int. J. Cancer 118(7), 1609-1617 (2006).
78. Mahtouk K, Hose D, Raynaud P et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109(11), 4914-4923 (2007).
79. Lerner I, Baraz L, Pikarsky E et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin. Cancer Res. 14(3), 668-676 (2008).
80. Brun R, Naroditsky I, Waterman M et al. Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. Mod. Pathol. 22(12), 1548-1554 (2009).
81. Jiang G, Zheng L, Pu J et al. Small RNAs targeting transcription start site induce heparanase silencing through interference with transcription initiation in human cancer cells. PLoS ONE 7(2), e31379 (2012).
82. Xiong Z, Lu MH, Fan YH et al. Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo. Int. J. Oncol. 40(5), 1601-1609 (2012).
83. Barash U, Arvatz G, Farfara R et al. Clinical significance of heparanase splice variant (T5) in renal cell carcinoma: evaluation by a novel T5-specific monoclonal antibody. PLoS ONE 7(12), e51494 (2012).
84. Meirovitz A, Goldberg R, Binder A, Rubinstein AM, Hermano E, Elkin M. Heparanase enzyme in inflammation and inflammation-associated cancer. FEBS J. 280(10), 2307-2319 (2013).
85. Brunn GJ, Bungum MK, Johnson GB, Platt JL. Conditional signaling by Toll-like receptor 4. FASEB J. 19(7), 872-874 (2005).
86. Parish CR. The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 6(9), 633-643 (2006).
87. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 20(1), 9-22 (2006).
88. Bode L, Salvestrini C, Park PW et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J. Clin. Invest. 118(1), 229-238 (2008).
89. Akbarshahi H, Axelsson JB, Said K, Malmstrom A, Fischer H, Andersson R. TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J. Transl. Med. 9, 219 (2011).
90. Axelsson J, Xu D, Kang BN et al. Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood 120(8), 1742-1751 (2012).
91. Li RW, Freeman C, Yu D et al. Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum. 58(6), 1590-1600 (2008).
92. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res. 7(5), 1299-1305 (2001).
93. Koliopanos A, Friess H, Kleeff J et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 61(12), 4655-4659 (2001).
94. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, Ilan N. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod. Pathol. 20(1), 8-14 (2007).
95. Lerner I, Hermano E, Zcharia E et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest. 121(5), 1709-1721 (2011).
96. Zhang X, Wang B, O'Callaghan P et al. Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathol. 124(4), 465-478 (2012).
97. Trebicz-Geffen M, Robinson D, Evron Z et al. The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. Int. J. Exp. Pathol. 89(5), 321-331 (2008).
98. Huegel J, Enomoto-Iwamoto M, Sgariglia F, Koyama E, Pacifici M. Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage: A mechanism possibly involved in hereditary multiple exostoses. Am. J. Pathol. 185(6), 1676-1685 (2015).
99. Oya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. World J. Orthop. 6(8), 590-601 (2015).
100. Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J. Bone Joint Surg. Am. 88(5), 1117-1132 (2006).
101. Peled E, Davis M, Axelman E, Norman D, Nadir Y. Heparanase role in the treatment of avascular necrosis of femur head. Thromb. Res. 131(1), 94-98 (2013).
102. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr. Endocrinol. Rev. 2, 437-448 (2013).
103. Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J. Biol. Chem. 282(2), 1080-1086 (2007).
104. O'Connell MP, Billings PC, Fiori JL et al. HSPG modulation of BMP signaling in fibrodysplasia ossificans progressiva cells. J. Cell Biochem. 102(6), 1493-1503 (2007).
105. Westermark GT, Westermark P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett. 583(16), 2685-2690 (2009).
106. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J. Struct. Biol. 130(2-3), 88-98 (2000).
107. Wang B, Tan Y-X, Jia J et al. Accelerated resolution of AA amyloid in heparanase knockout mice is associated with matrix metalloproteases. PLoS ONE 7(7), e39899 (2012).
108. Bornstein J, Cohen Y, Zarfati D, Sela S, Ophir E. Involvement of heparanase in the pathogenesis of localized vulvodynia. Int. J. Gynecol. Pathol. 27(1), 136-141 (2008).
109. Riaz A, Ilan N, Vlodavsky I, Li J-P, Johansson S. Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J. Biol. Chem. 288(17), 12366-12375 (2013).
110. Harisi R, Jeney A. Extracellular matrix as target for antitumor therapy. OncoTargets Ther. 8, 1387-1398 (2015).
111. Hu X, Zhang L, Jin J et al. Heparanase released from mesenchymal stem cells activates integrin beta1/HIF-2alpha/Flk-1 signaling and promotes endothelial cell migration and angiogenesis. Stem Cells 33(6), 1850-1862 (2015).
112. Munguti J, Sammy M. Mechanisms of tumor metastasis: anatomical mimicry? OA Anatomy 1(3), 23 (2013).
113. Linhardt RJ, Galliher PM, Cooney CL. Polysaccharide lyases. Appl. Biochem. Biotech. 12(2), 135-176 (1986).
114. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V. Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res. 43(6), 2704-2711 (1983).
115. Edovitsky E, Elkin M, Zcharia E, Perez T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J. Natl Cancer Inst. 96(16), 1219-1230 (2004).
116. Freeman C, Parish CR. A rapid quantitative assay for the detection of mammalian heparanase activity. Biochem. J. 325(Pt 1), 229-237 (1997).
117. Fairweather JK, Hammond E, Johnstone KD, Ferro V. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88. Bioorg. Med. Chem. 16(2), 699-709 (2008).
118. Bame KJ, Hassall A, Sanderson C, Venkatesan I, Sun C. Partial purification of heparanase activities in Chinese hamster ovary cells: evidence for multiple intracellular heparanases. Biochem. J. 336(Pt 1), 191-200 (1998).
119. Xu Y-J, Miao H-Q, Pan W et al. N-(4-{[4-(1HBenzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors. Bioorg. Med. Chem. Lett. 16(2), 404-408 (2006).
120. Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J. Biol. Chem. 274(34), 24153-24160 (1999).
121. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, Steinkühler C. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43(7), 1862-1873 (2004).
122. Enomoto K, Okamoto H, Numata Y, Takemoto H. A simple and rapid assay for heparanase activity using homogeneous time-resolved fluorescence. J. Pharm. Biomed. Anal. 41(3), 912-917 (2006).
123. Behzad F, Brenchley PE. A multiwell format assay for heparanase. Anal. Biochem. 320(2), 207-213 (2003).
124. Nakajima M, Welch DR, Irimura T, Nicolson GL. Basement membrane degradative enzymes as possible markers of tumor metastasis. Prog. Clin. Biol. Res. 212, 113-122 (1986).
125. Nakajima M, Irimura T, Nicolson GL. Tumor metastasisassociated heparanase (heparan sulfate endoglycosidase) activity in human melanoma cells. Cancer Lett. 31(3), 277-283 (1986).
126. Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J. 330(Pt 3), 1341-1350 (1998).
127. Tsuchida S, Podyma-Inoue KA, Yanagishita M. Ultrafiltration-based assay for heparanase activity. Anal. Biochem. 331(1), 147-152 (2004).
128. Karoli T, Liu L, Fairweather JK et al. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J. Med. Chem. 48(26), 8229-8236 (2005).
129. Xu X, Quiros RM, Maxhimer JB et al. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: A potential role in tumor metastasis. Clin. Cancer Res. 9(16 Pt1), 5968-5979 (2003).
130. Huang KS, Holmgren J, Reik L et al. High-throughput methods for measuring heparanase activity and screening potential antimetastatic and anti-inflammatory agents. Anal. Biochem. 333(2), 389-398 (2004).
131. Enomoto K, Okamoto H, Numata Y, Takemoto H. A simple and rapid assay for heparanase activity using homogeneous time-resolved fluorescence. J. Pharm. Biomed. Anal. 41(3), 912-917 (2006).
132. Roy S, El Hadri A, Richard S et al. Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure-activity relationship studies. J. Med. Chem. 57(11), 4511-4520 (2014).
133. Achour O, Poupard N, Bridiau N et al. Anti-heparanase activity of ultra-low-molecular-weight heparin produced by physicochemical depolymerization. Carbohydr. Polym. 135, 316-323 (2016).
134. Courtney SM, Hay PA, Buck RT et al. 2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: A novel class of small molecule heparanase inhibitors. Bioorg. Med. Chem. Lett. 14(12), 3269-3273 (2004).
135. Hammond E, Li CP, Ferro V. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening. Anal. Biochem. 396(1), 112-116 (2010).
136. Schiemann S, Lühn S, Alban S. Development of both colorimetric and fluorescence heparinase activity assays using fondaparinux as substrate. Anal. Biochem. 427(1), 82-89 (2012).
137. Mucciolo Melo C, Tersariol ILS, Nader HB, Pinhal MA, Lima MA. Development of new methods for determining the heparanase enzymatic activity. Carbohydr. Res. 412, 66-70 (2015).
138. Gandhi NS, Freeman C, Parish CR, Mancera RL. Computational analyses of the catalytic and heparinbinding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-d-glucuronidase (heparanase). Glycobiology 22(1), 35-55 (2012).
139. Bisio A, Mantegazza A, Urso E et al. High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase. Semin. Thromb. Hemost. 33(5), 488-495 (2007).
140. Chen J, Zhou Y, Chen C, Xu W, Yu B. Synthesis of a tetrasaccharide substrate of heparanase. Carbohydr. Res. 343(17), 2853-2862 (2008).
141. Pearson AG, Kiefel MJ, Ferro V, von Itzstein M. Synthesis of simple heparanase substrates. Org. Biomol. Chem. 9(12), 4614-4625 (2011).
142. Takeda N, Ikeda-Matsumi R, Ebara-Nagahara K et al. Synthesis of heparan sulfate tetrasaccharide as a substrate for human heparanase. Carbohydr. Res. 353, 13-21 (2012).
143. McKenzie E, Young K, Hircock M et al. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem. J. 373(Pt 2), 423-435 (2003).
144. Marchetti D, Reiland J, Erwin B, Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int. J. Cancer 104(2), 167-174 (2003).
145. Nadanaka S, Purunomo E, Takeda N, Tamura J, Kitagawa H. Heparan sulfate containing unsubstituted glucosamine residues. J. Biol. Chem. 289(22), 15231-15243 (2014).
146. Ishida K, Hirai G, Murakami K et al. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Mol. Cancer Ther. 3(9), 1069-1077 (2004).
147. Naggi A, Casu B, Perez M et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J. Biol. Chem. 280(13), 12103-12113 (2005).
148. Cochran S, Li C, Fairweather JK, Kett WC, Coombe DR, Ferro V. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J. Med. Chem. 46(21), 4601-4608 (2003).
149. Zhou H, Roy S, Cochran E et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 6(6) e21106 (2011).
150. Ferro V, Hammond E, Fairweather JK. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev. Med. Chem. 4(6), 693-702 (2004).
151. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z. Development of heparanase inhibitors for anti-cancer therapy. Curr. Med. Chem. 13(18), 2101-2111 (2006).
152. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparinderived mimetics of heparan sulfate. Curr. Pharm. Des. 13(20), 2057-2073 (2007).
153. Parish CR, Coombe DR, Jakobsen KB, Bennett FA, Underwood PA. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. Int. J. Cancer 40(4), 511-518 (1987).
154. Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int. J. Cancer 83(3), 424-431 (1999).
155. Saiki I, Murata J, Nakajima M, Tokura S, Azuma I. Saiki I, Murata J, Nakajima M, Tokura S, Azuma I. Cancer Res. 50(12), 3631-3637 (1990).
156. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 59(14), 3433-3441 (1999).
157. Lauver DA, Lucchesi BR. Sulodexide: A renewed interest in this glycosaminoglycan. Cardiovasc. Drug Rev. 24(3-4), 214-226 (2006).
158. Masola V, Onisto M, Zaza G, Lupo A, Gambaro G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial mesenchymal transition. J. Transl. Med. 10, 213 (2012).
159. Freeman C, Liu L, Banwell MG et al. Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins. J. Biol. Chem. 280(10), 8842-8849 (2005).
160. He X, Brenchley PE, Jayson GC, Hampson L, Davies J, Hampson IN. Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res. 64(11), 3928-3933 (2004).
161. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J. Am. Soc. Nephrol. 15(1), 68-78 (2004).
162. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA. Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology (Carlton) 10(2), 167-173 (2005).
163. Myler HA, Lipke EA, Rice EE, West JL. Novel heparanaseinhibiting antibody reduces neointima formation. J. Biochem. 139(3), 339-345 (2006).
164. Yang JM, Wang HJ, Du L et al. Screening and identification of novel B cell epitopes in human heparanase and their anti-invasion property for hepatocellular carcinoma. Cancer Immunol. Immunother. 58(9), 1387-1396 (2009).
165. Barash U, Arvatz G, Farfara R et al. Clinical significance of heparanase splice variant (t5) in renal cell carcinoma: evaluation by a novel t5-specific monoclonal antibody. PLoS ONE 7(12), e51494 (2012).
166. Weissmann M, Arvatz G, Horowitz N et al. Heparanaseneutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc. Natl Acad. Sci. USA 113(3), 704-709 (2016).
167. Fu J, Zhao B, Dong Z et al. Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models. Vaccine 30(12), 2187-2196 (2012).
168. Tang XD, Wang GZ, Guo J et al. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo. Mol. Cancer Ther. 11(5), 1183-1192 (2012).
169. Wang GZ, Tang XD, Lü MH et al. Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors. Cancer Prev. Res. (Phila.) 4(8), 1285-1295 (2011).
170. Zhang J, Yang JM, Wang HJ, Ru GQ, Fan DM. Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo. PLoS ONE 8(1), e52940 (2013).
171. Zhang J, Yang J, Cai Y, Jin N, Wang H, Yu T. Multiple antigenic polypeptide composed of heparanase B-cell epitopes shrinks human hepatocellular carcinoma in mice. Oncol. Rep. 33(3), 1248-1256 (2015).
172. Tang XD, Guo SL, Wang GZ et al. In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies. Cancer Sci. 105(1), 9-17 (2014).
173. Mitsiades CS, Rouleau C, Echart C et al. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin. Cancer Res. 15(4), 1210-1221 (2009).
174. Huining L, Yi Z, Dihong T et al. Inhibition of choriocarcinoma by Fe3O4-dextran-anti-β-human chorionic gonadotropin nanoparticles containing antisense oligodeoxynucleotide of heparanase. Int. J. Nanomedicine 8(1), 4371-4378 (2013).
175. Simmons SC, McKenzie EA, Harris LK et al. Development of novel single-stranded nucleic acid aptamers against the pro-angiogenic and metastatic enzyme heparanase (HPSE1). PLoS ONE 7(6), e37938 (2012).
176. Simmons SC, Jämsä H, Silva D et al. Anti-heparanase aptamers as potential diagnostic and therapeutic agents for oral cancer. PLoS ONE 9(10), e96846 (2014).
177. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M. Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107(9), 3609-3616 (2006).
178. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J. Natl Cancer. Inst. 96(16), 1219-1230 (2004).
179. Dong W, Zhao H, Zhang C et al. Gene silencing of heparanase results in suppression of invasion and migration of hepatoma cells. World J. Surg. Oncol. 12, 85 (2014).
180. Xiong Z, Lü MH, Fan YH et al. Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo. Int. J. Oncol. 40(5), 1601-1609 (2012).
181. Jiang G, Zheng L, Pu J et al. Small RNAs targeting transcription start site induce heparanase silencing through interference with transcription initiation in human cancer cells. PLoS ONE 7(2), e31379 (2012).
182. Liu M, Zhang Y, Liao Y et al. Evaluation of the antitumor efficacy of RNAi-mediated inhibition of CDC20 and heparanase in an orthotopic liver tumor model. Cancer Biother. Radiopharm. 30(6), 233-239 (2015).
183. Liu X, Fang H, Chen H et al. An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS ONE 7(6), e38659 (2012).
184. Liu XY, Tang QS, Chen HC, Jiang XL, Fang H. Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. Int. J. Biol. Sci. 9(6), 564-577 (2013).
185. Shiozawa H, Takahashi H, Takatsu T et al. Trachyspic acid, a new metabolite produced by Talaromyces trachyspermus, that inhibits tumor cell heparanase: taxonomy of the producing strain, fermentation, isolation, structural elucidation, and biological activity. J. Antibiot. 48(5), 357-362 (1995).
186. Jpn. Kokai Tokkyo Koho JP 05086085A (1993).
187. Shiozawa H, Takahashi M, Takatsu T et al. Trachyspic acid, a new metabolite produced by Talaromyces trachyspermus, that inhibits tumor cell heparanase: taxonomy of the producing strain, fermentation, isolation, structural elucidation, and biological activity. J. Antibiot. (Tokyo) 48(5), 357-362 (1995).
188. Zammit S, Ferro V, Hammond E, Rizzacasa MA. Enantiospecific synthesis of the heparanase inhibitor (+)-trachyspic acid and stereoisomers from a common precursor. Org. Biomol. Chem. 5(17), 2826-2834 (2007).
189. Nakajima M, DeChavigny A, Johnson CE, Hamada J, Stein CA, Nicolson GL. Suramin. A potent inhibitor of melanoma heparanase and invasion. J. Biol. Chem. 266(15), 9661-9666 (1991).
190. Ishida K, Hirai G, Murakami K et al. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Mol. Cancer Ther. 3(9), 1069-1077 (2004).
191. Insight Strategy and Marketing Ltd: WO02060373 (2002).
192. Insight Strategy and Marketing Ltd: WO02060375 (2002).
193. Insight Strategy and Marketing Ltd: WO02060867 (2002).
194. Marchetti D, Reiland J, Erwin B, Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int. J. Cancer 104(2), 167-174 (2003).
195. Li H, Li H, Qu H et al. Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression. Cancer Cell. Int. 15, 52 (2015).
196. Roggo BE, Petersen F, Delmendo R, Jenny HB, Peter HH, Roesel J. 3-alkanoyl-5-hydroxymethyl tetronic acid omologues and resistomycin: new inhibitors of HIV-1 protease I. Fermentation, isolation and biological activity. J. Antibiot. 47(2), 136-142 (1994).
197. Courtney SM, Hay PA, Buck RT et al. Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. Bioorg. Med. Chem. Lett. 15(9), 2295-2299 (2005).
198. Pan W, Miao HQ, Xu YJ et al. 1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors. Bioorg. Med. Chem. Lett. 16(2), 409-412 (2006).
199. Gozalbes R, Mosulén S, Ortí L et al. Hit identification of novel heparanase inhibitors by structure-and ligand-based approaches. Bioorg. Med. Chem. 21(7), 1944-1951 (2013).
200. Basappa, , Murugan S, Kavitha CV et al. A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-α. Cancer Lett. 297(2), 231-243 (2010).
201. Kawase Y, Takahashi M, Takatsu T, Arai M, Nakajima M, Tanzawa K. A-72363 A-1, A-2, and C, novel heparanase inhibitors from Streptomyces nobilis SANK 60192, II. Biological activities. J. Antibiot. (Tokyo) 49(1), 61-64 (1996).
202. Nishimura Y, Shitara E, Adachi H et al. Flexible synthesis and biological activity of uronic acid-type gemdiamine 1-N-iminosugars: A new family of glycosidase inhibitors. J. Org. Chem. 65(1), 2-11 (2000).
203. Dredge K, Hammond E, Davis K et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest. New Drugs 28(3), 276-283 (2010).
204. Hammond E, Handley P, Dredge K, Bytheway I. Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues. FEBS Open Biol. 3, 346-351 (2013).
205. Page C. Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol. 2013, 910743 (2013).
206. Lapierre F, Holme K, Lam L et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and antimetastatic properties. Glycobiology 6(3), 355-366 (1996).
207. Casu B, Guerrini M, Naggi A et al. Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry 41(33), 10519-10528 (2002).
208. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: A novel inhibitor of angiogenesis. Expert Opin. Investig. Drugs 17(11), 1769-1776 (2008).
209. Medigen Press Release July 29th, 2014. www.medigen.com.tw/en/further-explanation/
210. Brennan TV, Lin L, Brandstadter JD et al. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J. Clin. Invest. 126(1), 207-219 (2016)
211. Ferro V, Liu L, Johnstone KD et al. Discovery of PG545: A highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J. Med. Chem. 55(8), 3804-3813 (2012).
212. Winterhoff B, Freyer L, Hammond E et al. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur. J. Cancer 51(7), 879-892 (2015).
213. Cassinelli G, Lanzi C, Tortoreto M et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem. Pharmacol. 85(10), 1424-1432 (2013).
214. Shafat I, Ben-Arush MW, Issakov J et al. Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J. Cell Mol. Med. 15(9), 1857-1864 (2011).
215. Zhang L, Ngo JA, Wetzel MD, Marchetti D. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia 17(1), 101-113 (2015).
216. Meirovitz A, Hermano E, Lerner I et al. Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res. 71(7), 2772-2780 (2011).
217. Ritchie JP, Ramani VC, Ren Y et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 17(6), 1382-1393 (2011).
218. Ramani VC, Zhan F, He J et al. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget 7(2), 1598-1607 (2016).
219. Galli M, Magen H, Einsele H et al. Roneparstat (SST0001), an innovative heparanase (HPSE) inhibitor for multiple myeloma (MM) therapy: first in man study. Blood Abstracts: 57th Annual Meeting Abstracts 126(23), 3246 (2015).
220. Momenta Pharmeuticals Press Releases Nov 13th 2015 http://ir.momentapharma.com/releasedetail.cfm
221. Shteingauz A, Boyango I, Naroditsky I. Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Res. 75(18), 3946-3957 (2015).
222. Wu X, Yu J, Gao G et al. Salivary heparanase level is a potential biomarker to diagnose and prognose the malignant salivary gland tumor. PLoS ONE 10(11), e0143009 (2015).
223. Leiser Y, Shilo D, Abu El Naaj I, Rachmiel A. Heparanase, a potential marker for premalignant oral cavity cancer. In vivo 28(5), 769-777 (2014).
224. Zcharia E, Jia J, Zhang X et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE 4(4), e5181 (2009).